Immunic to Participate in Scientific and Investor Conference

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Related Keywords

Boston , Massachusetts , United States , New York , Missoula , Montana , Ukraine , Germany , Beth Israel Medical Center , Adams Center , Russia , Rochester , Josepha Murray , Jessica Breu , Friedrich Hahn , Paula Schwartz , J Thomas Lamont , Edna Kaplan , Martina Wirth , Nasdaq , Beth Israel Deaconess Medical Center , Institute For Clinical , Celiac Disease Research , Adams Center Ancillary Gyms , Division Of Gastroenterology , Department Of Internal Medicine , Shirley Berry Professor Of Gastrointestinal Sciences , Celiac Center , Selective Small Molecules Directed To Nuclear Receptor , Securities Therapeutics Forum Daniel Vitt , International Herpesvirus Workshop , Rx Communications Group , Harvard Medical School , Immunic Inc , Exchange Commission , Mucosal Immunology , Translational View , Clinic Martina Wirth , Manager Translational Pharmacology , Human Trial , Orally Available Epigenetic Modulator , Barrier Function , Poster Number , Therapeutics Forum Daniel Vitt , Chief Executive Officer , Annual International Herpesvirus , Selective Small Molecules Directed , Nuclear Receptor , Poster Session , Session Location , Adams Center Ancillary , Presentation Location , Molecular Virology , Celiac Disease , Director Celiac Center , Shirley Berry Professor , Gastrointestinal Sciences , Internal Medicine , Mayo Clinic , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Immunic , Nc ,